Targeted alpha anticancer therapies: update and future prospects
Barry J Allen,1,2 Chen-Yu Huang,3 Raymond A Clarke2 1Faculty of Physics, University of Sydney, Sydney, NSW, Australia; 2Faculty of Medicine, Ingham Institute, University of Western Sydney, Liverpool, NSW, Australia; 3Central Clinical School, University of Sydney, Sydney, NSW, AustraliaAbstract: Targeted alpha therapy (TAT) is an emerging option for local and systemic cancer treatment. Preclinical research and clinical trials show that alpha-emitting radionuclides can kill targeted cancer cells while sparing normal cells, thus reducing toxicity. 223RaCl2 (Xofigo®) is the first alpha emitting radioisotope to gain registr...
Source: Biologics: Targets and Therapy - November 9, 2014 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Targeted alpha anticancer therapies update and future prospects
Allen BJ, Huang CY, Clarke RA (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - November 9, 2014 Category: Biochemistry Source Type: research
Resistant mutations in CML and Ph+ALL & ndash; role of ponatinib
(Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - October 20, 2014 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Resistant mutations in CML and Ph+ALL – role of ponatinib
Geoffrey D Miller, Benjamin J Bruno, Carol S LimDepartment of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, Utah, USAAbstract: In 2012, ponatinib (Iclusig®), an orally available pan-BCR-ABL tyrosine kinase inhibitor (TKI) developed by ARIAD Pharmaceuticals, Inc., was approved by the US Food and Drug Administration for use in resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Ponatinib is the only approved TKI capable of inhibiting BCR-ABL with the gatekeeper T315I kinase domain mutation...
Source: Biologics: Targets and Therapy - October 20, 2014 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Use of ponatinib in CML and Ph+ALL
Miller GD, Bruno BJ, Lim CS (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - October 19, 2014 Category: Biochemistry Source Type: research
Botulinum toxin type A products are not interchangeable: a review of the evidence
Mitchell F Brin,1,2 Charmaine James,3 John Maltman1 1Allergan, Inc., Irvine, CA, USA; 2Department of Neurology, University of California, Irvine, CA, USA; 3Allergan, Marlow, UKAbstract: Botulinum toxin type A (BoNTA) products are injectable biologic medications derived from Clostridium botulinum bacteria. Several different BoNTA products are marketed in various countries, and they are not interchangeable. Differences between products include manufacturing processes, formulations, and the assay methods used to determine units of biological activity. These differences result in a specific set of interactions between each BoN...
Source: Biologics: Targets and Therapy - October 6, 2014 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
BoNT differences
Brin MF, James C, Maltman J (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - October 5, 2014 Category: Biochemistry Source Type: research
New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
Franco Frati,1 Lorenzo Cecchi,2,3 Enrico Scala,4 Erminia Ridolo,5 Ilaria Dell'Albani,1 Eleni Makrì,6 Giovanni Pajno,7 Cristoforo Incorvaia61Medical and Scientific Department, Stallergenes, Milan, Italy; 2Interdepartmental Centre of Bioclimatology, University of Florence, Florence, Italy; 3Allergy and Clinical Immunology Section, Azienda Sanitaria di Prato, Prato, Italy; 4Experimental Allergy Unit, IDI-IRCCS, Rome, Italy; 5Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy; 6Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, Italy; 7Department of Pediatrics, Allergy Unit, Univ...
Source: Biologics: Targets and Therapy - September 12, 2014 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Management of allergic rhinitis
Frati F, Cecchi L, Scala E, Ridolo E, Dell'Albani I, Makrì E, Pajno G, Incorvaia C (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - September 11, 2014 Category: Biochemistry Source Type: research
Management of allergic rhinitis
Frati F, Cecchi L, Scala E, Ridolo E, Dell'Albani I, Makrì E, Pajno G, Incorvaia C (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - September 11, 2014 Category: Biochemistry Source Type: research
Apoptosis as pharmacodynamic criteria for biosimilar TNF-a antagonists
Urbano PCM, Soccol VT, Azevedo VF (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - July 30, 2014 Category: Biochemistry Source Type: research
